IR Overview

Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer immunotherapy products. We utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets on cancer cells. We engineer a patient’s own T-cells to express our SPEAR TCRs to target and potentially destroy tumors.

Our wholly-owned pipeline includes SPEAR T-cell therapies targeting MAGE-A10, MAGE-A4, and AFP, which are being investigated in clinical studies across multiple solid tumor indications. We continue to build a pipeline of further proprietary TCR therapeutic candidates, second generation treatment options, as well as allogeneic (off-the-shelf) solutions.

We believe our approach will lead to SPEAR T-cells with the potential to significantly impact cancer treatment and the clinical outcomes of cancer patients.

$5.16 Stock is Down 0.2 (3.73%)
ADAP (American Depositary Shares)
ExchangeNASDAQ GS (US Dollar)
Today's Open$5.27
Previous Close$5.36
Data as of 12/14/18 4:00 p.m.
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Recent NewsMore >>
12/12/18Adaptimmune Announces that Gwen Binder will leave in January 2019
PHILADELPHIA and OXFORD, United Kingdom, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Adaptimmune (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that Gwen Binder, PhD, Chief Technology Officer, will be leaving the company at the end of January 2019. Dr. Binder was the first US employee of Adaptimmune in 2011, transitioning across from the company’s T-cell translational development collaboration program with the University of Pennsylvania. She led much of the early clinical... 
Printer Friendly Version
11/06/18Adaptimmune Reports Third Quarter 2018 Financial Results and Business Update
Progressed to expansion phase for MAGE-A10 triple tumor and MAGE-A4 basket studies after favorable safety review of Cohort 3 data with target doses of 5 billion cells Continued dosing in Cohort 1 of AFP study, with anticipated dose escalation to Cohort 2 early 2019  ~$26 million upon completion of transition of NY-ESO SPEAR T-cell program IND to GSK Closed registered direct offering with net proceeds of ~$100 million; guidance updated, funded to late 2020 Conference call to be held toda... 
Printer Friendly Version
10/25/18Adaptimmune to Report Third Quarter 2018 Financial Results and Business Update on Tuesday, November 6, 2018
PHILADELPHIA and OXFORD, United Kingdom, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the Third Quarter 2018 and provide a general business update before the U.S. markets open on Tuesday, November 6, 2018. Following the announcement, the company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT) on the same day. The press release and the live webcast of ... 
Printer Friendly Version
10/20/18Updated Data from Ongoing MAGE-A10 and MAGE-A4 Studies Presented at the 2018 ESMO Congress
PHILADELPHIA and OXFORD, United Kingdom, Oct. 20, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, presented initial data from the first two cohorts of its ongoing studies with its MAGE-A10 and MAGE-A4 SPEAR T-cells in two poster presentations earlier today at the European Society for Medical Oncology (ESMO) Congress in Munich, Germany. “We are encouraged by the safety data from these initial cohorts, which inc... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Adaptimmune posts new information to the site. Just enter your e-mail address and click Submit.